← Back to directory
Not currently recruitingFunding unknown
- Works count
- 43
- Citation count
- 13,361
- H-index
- 19
- i10-index
- 21
Research interests
Medicine
Cancer Immunotherapy and Biomarkers
Gastric Cancer Management and Outcomes
Gastrointestinal Tumor Research and Treatment
Lung Cancer Treatments and Mutations
Esophageal Cancer Research and Treatment
Publications
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
Journal of Clinical Oncology · 2022 · 10.1200/jco.21.02885
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
JAMA Oncology · 2020 · 10.1001/jamaoncol.2020.3370
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
The Lancet · 2019 · 10.1016/s0140-6736(18)32409-7
Current projects
No projects listed.